Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Jaguar Health, Inc. JAGX

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 4, 2026 8-K 0 signals fired
No signals above threshold for this filing.
Aug 19, 2026 10-Q 45 signals fired · top 15
Other
Financing Activities Cash Flow Disclosure Warrant Valued Black Scholes Nasdaq Minimum Bid Price Delisting Notice Ipo Net Proceeds Disclosure Net Loss Reported Reverse Stock Split Effected Administrative Efficiency Personnel Cost Decrease Disclosure Burn Rate Controlled Institutional Investment Fair Value Hierarchy Reconciliation Disclosed Interim Data Positive Termination For Material Breach Clause Segment Aggregation Disclosure
Core
Regulatory Designation Only
Jul 14, 2026 8-K 12 signals fired
Other
Fcpa Compliance Representation Confidential Information Return Obligation Indemnification Consent Requirement Corporate Authority Representation Conflicted Defense Counsel Provision Termination For Material Breach Clause Arbitrator Selection Procedure Amendment Modification Waiver Clause Non Assignment Clause Survival Of Representations Warranties Clause Registration Rights Piggyback Provision New York Jurisdiction Clause
Jul 1, 2026 8-K 1 signal fired
Other
Convertible Debt Conversion
Jun 25, 2026 8-K 7 signals fired
Other
Quarterly Dividend Declared Interim Data Positive Expanded Access Program Active Record Date Disclosure Form 8K Filing Disclosure
Core
Lead Asset Progress Clinical Hold
Jun 22, 2026 8-K 2 signals fired
Other
Expanded Access Program Active
Core
Clinical Trial Result
Jun 18, 2026 8-K 1 signal fired
Other
Debt Note Maturity Date Disclosure
Jun 11, 2026 8-K 26 signals fired · top 15
Other
Amendment Modification Waiver Clause New York Jurisdiction Clause Indemnification Consent Requirement Fcpa Compliance Representation Market Price Definition Registration Rights Piggyback Provision Sanctions Compliance Representation Survival Of Representations Warranties Clause Erisa Definition Or Compliance Statement No Broker Fees Representation Use Of Proceeds Disclosure Transfer And Demand Rights Limitations Nyse Listing Disclosure Non Assignment Clause Employment Termination Upon Death
Jun 8, 2026 8-K 1 signal fired
Other
Quorum Presence Disclosed
Jun 2, 2026 8-K 1 signal fired
Other
Annual Meeting Notice Disclosure
May 27, 2026 8-K 4 signals fired
Other
Nasdaq Minimum Bid Price Delisting Notice
Core
Indication Expansion Lead Asset Progress
Biotech Risk
Crl Received
May 22, 2026 8-K 2 signals fired
Other
Annual Meeting Notice Disclosure Merger Proxy Statement Disclosure
May 20, 2026 10-Q 31 signals fired · top 15
Other
Fair Value Hierarchy Disclosure Nasdaq Minimum Bid Price Delisting Notice Warrant Valued Black Scholes Financing Activities Cash Flow Disclosure Reverse Stock Split Effected Convertible Debt Conversion Net Loss Reported Institutional Investment Fair Value Hierarchy Reconciliation Disclosed Segment Aggregation Disclosure Cash Flow Statement Investing Activities Quarterly Dividend Declared Convertible Notes Conversion Terms Disclosed Equity Plan Board Approval Conditional On Shareholder Vote Litigation Defense Assertion
May 19, 2026 8-K 1 signal fired
Other
Amendment Modification Waiver Clause
May 7, 2026 8-K 1 signal fired
Other
Nasdaq Minimum Bid Price Delisting Notice
May 4, 2026 8-K 2 signals fired
Other
Nasdaq Minimum Bid Price Delisting Notice Reverse Stock Split Effected
May 4, 2026 8-K 2 signals fired
Other
Institutional Investment Reverse Stock Split Effected
Apr 27, 2026 8-K 3 signals fired
Other
Nasdaq Minimum Bid Price Delisting Notice Reverse Stock Split Effected Nyse Listing Disclosure
Apr 21, 2026 8-K 1 signal fired
Other
Adjournment Proposal Voting Requirement
Apr 7, 2026 10-K 93 signals fired · top 15
Other
Fair Value Hierarchy Disclosure Use Of Proceeds Disclosure Nasdaq Minimum Bid Price Delisting Notice Cash Flow Statement Investing Activities Headcount Disclosure Standard Segment Aggregation Disclosure Ipo Net Proceeds Disclosure Reverse Stock Split Effected Fifo Inventory Valuation Disclosed Capital Raising Uncertainty Disclosed Quarterly Dividend Declared Vie Primary Beneficiary Disclosure Convertible Debt Conversion Net Loss Reported
Biotech Risk
Trial Endpoint Missed